Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151749 · ClinicalTrials.gov registry record · Phase 3
WelChol® and Insulin in Treating Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
NCT00151749 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 260 participants.
The verdict
NCT00151749, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
Study Summary
The purpose of the study is to see how safe and effective and tolerable the use of WelChol® is for type 2 diabetes when added to insulin alone or in combination with other anti-diabetic drugs
Interventions
- DRUG Colesevelam hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2004-06 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151749
The ClinicalTrials.gov registry entry for NCT00151749 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Colesevelam hydrochloride is the first listed.
NCT00151749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00151749 about?
NCT00151749 is a clinical study titled "WelChol® and Insulin in Treating Patients With Type 2 Diabetes". The purpose of the study is to see how safe and effective and tolerable the use of WelChol® is for type 2 diabetes when added to insulin alone or in combination with other anti-diabetic drugs
What is the current status of trial NCT00151749?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2004-06. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00151749?
The interventions under investigation include: Colesevelam hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00151749?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.